BOLT (Bolt Biotherapeutics) Short Interest


BOLT Bolt Biotherapeutics Inc BOLT
55 GF Score
Price $4.22
GF Value $9.03
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Bolt Biotherapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

BOLT vs BCDA, NCNA, PBM: Short Interest Comparison

For the Biotechnology subindustry, Bolt Biotherapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bolt Biotherapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bolt Biotherapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Bolt Biotherapeutics's Short Interest falls into.


BOLT
55GF Score
Bolt Biotherapeutics Inc BOLT
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bolt Biotherapeutics (BOLT) Overvalued in 2026?

Based on GuruFocus' analysis, Bolt Biotherapeutics stock appears to be undervalued. The current stock price of $4.22 is trading 53.3% below its estimated GF Value™ of $9.03. GuruFocus considers Bolt Biotherapeutics to be Possible Value Trap.

Key valuation signals for BOLT:

  • Short Interest:
  • GF Value™: $9.03 vs. price of $4.22 (53.3% below fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the BOLT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bolt Biotherapeutics Business Description

Address 900 Chesapeake Drive, Redwood City, CA, USA, 94063
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
55GF Score

Get the complete analysis for BOLT

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.22
Price
$9.03
GF Value